Ropivacaine

證據等級: L5

預測適應症: 10 個

Ropivacaine: From Regional Anaesthesia to Migraine Disorder

One-Sentence Summary

Ropivacaine is a long-acting amide local anaesthetic used in clinical practice for regional anaesthesia and interventional pain management procedures. The TxGNN model predicts it may be effective for Migraine Disorder, with 4 clinical trials and 6 publications currently supporting this direction. Evidence is at Level L2, anchored by a completed Phase 4 double-blind RCT and a paediatric emergency department trial involving 150 participants.

Quick Overview

Item	Content
Original Indication	Regional anaesthesia and pain management (no MHRA marketing authorisation on record)
Predicted New Indication	Migraine Disorder
TxGNN Prediction Score	99.65%
Evidence Level	L2
UK Market Status	Not marketed
Number of Marketing Authorisations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Ropivacaine is a long-acting amide local anaesthetic whose principal mechanism is voltage-gated sodium channel (Nav channel) blockade, inhibiting the initiation and propagation of nerve action potentials. Although detailed mechanism of action data was not available in the current Evidence Pack, Nav-channel blockade is Ropivacaine’s well-established pharmacological basis and underpins every plausible route through which it could influence migraine.

The application to migraine is mechanistically coherent. Migraine pathophysiology involves activation of the trigeminovascular system, peripheral sensitisation of nociceptors around meningeal blood vessels, and amplification of pain signals through autonomic relay stations — most notably the sphenopalatine ganglion (SPG). Ropivacaine delivered via SPG block, trigger point injection, or stellate ganglion block can interrupt these pain transmission circuits directly. The SPG in particular plays a pivotal role in propagating both the pain and the autonomic features (lacrimation, nasal congestion) characteristic of migraine attacks, making it a recognised interventional target.

Early clinical data are encouraging. A completed Phase 4 double-blind RCT (NCT03666663) directly evaluated SPG blocks with local anaesthetics for migraine prevention, and a completed unphased trial (NCT00680823, n=150) studied intramuscular Ropivacaine for paediatric headache in an emergency department setting. Multiple observational studies provide further biological plausibility, with one 2007 prospective cohort study specifically evaluating Ropivacaine trigger point injections for prophylactic migraine management over 12 weeks. The convergence of mechanism, interventional precedent, and early-phase data makes the TxGNN prediction scientifically credible.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrolment	Key Findings
NCT00680823	N/A	Completed	150	Largest completed trial for this drug–indication pair: evaluated lower paracervical intramuscular Ropivacaine injection as a treatment for headache in a paediatric emergency department
NCT03666663	Phase 4	Completed	10	Double-blind RCT of SPG block using local anaesthetics vs placebo for migraine prevention in adults; directly relevant but substantially limited by very small sample size
NCT05301387	N/A	Completed	38	Assessed long-term effects of SPG block on post-dural puncture headache; mechanistically related (SPG pathway) but target population is PDPH rather than primary migraine
NCT06470581	N/A	Not yet recruiting	78	Prospective RCT comparing botulinum toxin A vs local anaesthetic for thoracic sympathetic ganglion block in upper-limb CRPS; Ropivacaine likely serves as comparator only — not yet commenced

Literature Evidence

PMID	Year	Type	Journal	Key Findings
35331152	2022	Observational Study	BMC Anesthesiology	Ultrasound-guided stellate ganglion block observed to effectively relieve migraine pain and improve quality of life; supports ganglion-blockade approach in migraine
30043973	2019	Observational Study	Headache	Regional anaesthetic SPG block reduced self-reported pain in status migrainosus (migraine >72 hours); reinforces SPG as a strategic therapeutic target
17244105	2007	Prospective Cohort	Pain Medicine	Ropivacaine trigger point injections over 12 weeks evaluated for prophylactic management of severe migraine; sole study directly assessing Ropivacaine for migraine prevention
24284858	2013	Case Series / Technique Report	Pain Physician	Described a revised transnasal topical SPG block technique for headache and facial pain; supports SPG as accessible interventional target with favourable risk profile
17058040	2006	Case Report	J Headache Pain	Migraine headache reported as rare complication after cervicothoracic block; provides indirect mechanistic insight into local anaesthetic–trigeminal pain circuit interactions
19145569	2009	Case Report	Revista de Neurologia	Horner’s syndrome following epidural analgesia; limited direct relevance to migraine treatment — included for completeness

Safety Considerations

Please refer to the SmPC and BNF for safety information. Report suspected adverse reactions via the Yellow Card Scheme.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: A completed Phase 4 RCT and the largest available paediatric headache trial (n=150) — together with a coherent Nav-channel / trigeminovascular mechanistic rationale and multiple supporting observational studies — provide an L2 evidence base sufficient to justify further development, provided appropriate safeguards are in place to address current data gaps.

To proceed, the following is needed:

Mechanism of action data: Retrieve full pharmacological profile from DrugBank to formalise the Nav-channel / trigeminovascular mechanistic narrative
Safety review: Obtain full SmPC (MHRA/EMA) to complete warnings, contraindications, and drug interaction profiling prior to any clinical development
Larger confirmatory RCT: A well-powered trial (target n ≥ 100) in adult primary migraine using SPG block with Ropivacaine; the existing Phase 4 trial (n=10) is underpowered to support regulatory claims
Dose and route standardisation: Define the optimal administration route (transnasal, infrazygomatic, or catheter-based SPG block) and dose range for the migraine indication
UK regulatory pathway: Consult MHRA regarding the route to a new indication given Ropivacaine currently holds no UK marketing authorisation; a Marketing Authorisation Application (MAA) or an off-label use framework would need to be identified
Paediatric data review: The NCT00680823 paediatric dataset (n=150) should be formally analysed and published to strengthen the evidence base
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.